pirfenidone

April 11, 2017April 11, 2017

Researchers Review Performance of Genentech’s Esbriet in Treating Idiopathic Pulmonary Fibrosis

Genentech’s Esbriet (pirfenidone), approved by the U.S. Food and Drug Administration (FDA) in 2014 to treat idiopathic pulmonary fibrosis (IPF), prolongs survival in patients and is generally safe, concludes a review, “Role ... Read more

March 23, 2017March 23, 2017

New Research Reveals How IPF Treatments Ofev and Esbriet Work

Idiopathic Pulmonary Fibrosis, News

Researchers from Germany have identified how Ofev (nintedanib) and Esbriet (pirfenidone) work — two FDA-approved drugs for the treatment of idiopathic pulmonary fibrosis (IPF). The study, titled “A Novel Antifibrotic Mechanism ... Read more

September 21, 2016September 21, 2016

New Data Supports Esbriet as Safe, Effective Treatment for IPF Patients

Idiopathic Pulmonary Fibrosis, News

Positive results from four analyses based on clinical trials developed by Roche to evaluate the effectiveness of Esbriet (pirfenidone), an oral antifibrotic medication approved by the U.S. Food and Drug ... Read more

August 8, 2016August 8, 2016

Early Treatment with Esbriet Can Help Slow IPF Progression, Study Finds

Idiopathic Pulmonary Fibrosis, News

Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease, and patients have very few options once the disease seriously progresses. Now, a study from the University of Turin, Italy, suggests ... Read more

March 18, 2016March 23, 2016

Study Finds IPF Patients Should Continue Pirfenidone Use Even as Disease Progresses

Idiopathic Pulmonary Fibrosis, News

An international group of researchers addressed an important clinical question about idiopathic pulmonary fibrosis (IPF) — Should people with IPF continue treatment with pirfenidone (Esbriet) if their disease meaningfully worsens? ... Read more

January 18, 2016January 19, 2016

Drug’s Safety for Idiopathic Pulmonary Fibrosis Supported by 5 Clinical Trials

Idiopathic Pulmonary Fibrosis, News

Research from an international, collaborative group of scientists, led by researchers at Vanderbilt University in Tennessee, supports the safety of pirfenidone as a therapy for idiopathic pulmonary fibrosis (IPF). The ... Read more

December 15, 2015December 15, 2015

New IPF Study to Test OFEV/Esbriet as Combination Therapy

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim announced that it has initiated a 12-week clinical trial investigating the safety, tolerability, and pharmacokinetics of pirfenidone (marketed as Esbriet by Genentech) as an add-on to treatment with OFEV (nintedanib). The ... Read more

August 13, 2015November 5, 2015

American Thoracic Society Recommends Esbriet (Pirfenidone) in Updated IPF Treatment Guidelines

Idiopathic Pulmonary Fibrosis, News

Esbriet (pirfenidone) by Genentech was recently included in the American Thoracic Society’s (ATS) updated idiopathic pulmonary fibrosis (IPF) treatment guidelines, which presents the drug’s proven benefits in delaying disease progression, as determined ... Read more

August 3, 2015November 5, 2015

Roche’s Pirfenidone (Esbriet) Found to Offer Therapeutic Benefit For IPF in a Clinical Practice Setting

Idiopathic Pulmonary Fibrosis, News

A new study recently published in the journal Advances in Therapy provided evidence of the therapeutic benefit of pirfenidone (known by the brand name Esbriet) for IPF patients in a ... Read more

July 2, 2015November 6, 2015

Study Presented at EULAR Shows Roche’s Esbriet Meets Safety Targets in Systemic Sclerosis-related Interstitial Lung Disease

News, Scleroderma

Results from a recent open-label trial presented during the European League Against Rheumatism Annual European Congress of Rheumatology showed that ESBRIET met its safety endpoint in the treatment of interstitial lung ... Read more